公开(公告)号：US20210238296A1

公开(公告)日：2021-08-05

申请号：US17051205

申请日：2019-05-03

Applicant: GENMAB B.V.

Inventor： Rob DE JONG ,  Frank BEURSKENS ,  Simone OOSTINDIE ,  Aran Frank LABRIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Bart-Jan DE KREUK

IPC: C07K16/28 ,  A61K45/06

Abstract: Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

公开(公告)号：US20210163619A1

公开(公告)日：2021-06-03

申请号：US16921154

申请日：2020-07-06

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  C07K16/36 ,  C07K16/00

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

公开(公告)号：US20150337049A1

公开(公告)日：2015-11-26

申请号：US14760157

申请日：2014-01-09

Applicant: GENMAB B.V.

Inventor： Aran Frank LABRIJN ,  Joyce MEESTERS ,  Joost J. NEIJSSEN ,  Edward Norbert VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Abstract translation: 本文描述的是在第一和第二多肽链中的至少一个中包含氨基酸取代的蛋白质。 此外，描述了与所述蛋白质相关的用途和方法。

公开(公告)号：US20250145720A1

公开(公告)日：2025-05-08

申请号：US18744540

申请日：2024-06-14

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Sandra VERPLOEGEN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  C07K16/00 ,  C07K16/36 ,  C07K16/40 ,  C07K19/00

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

公开(公告)号：US20210230301A1

公开(公告)日：2021-07-29

申请号：US17012102

申请日：2020-09-04

Applicant: GENMAB B.V.

Inventor： Rob N. DE JONG ,  Frank BEURSKENS ,  Paul PARREN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN ,  Arjen VLUG ,  Sandra VERPLOEGEN

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20150353636A1

公开(公告)日：2015-12-10

申请号：US14760135

申请日：2013-01-10

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Sandra VERPLOEGEN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  C07K16/40 ,  C07K19/00 ,  A61K51/10 ,  A61K39/395 ,  A61K47/48

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2319/30

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

Abstract translation: 本文描述的是包含变体Fc结构域的多肽和相关抗体。 当多肽，抗体或抗体与细胞表面上的靶标，抗原或抗原结合时，变体Fc结构域提供稳定的Fc：Fc相互作用，从而提供改善的补体依赖性细胞毒性（CDC）。